Ignite Creation Date:
2024-05-06 @ 7:53 AM
Last Modification Date:
2024-10-26 @ 11:53 AM
Study NCT ID:
NCT02626338
Status:
COMPLETED
Last Update Posted:
2023-12-20
First Post:
2015-11-18
Brief Title:
Pilot Study of Crenolanib Combined With Standard Salvage Chemotherapy in Subjects With RR AML
Sponsor:
Arog Pharmaceuticals Inc
Organization:
Arog Pharmaceuticals Inc
Study Overview
Official Title:
Pilot Study of Crenolanib Combined With Standard Salvage Chmetherapy in Subjects With RelapsedRefractory Acute Myeloid Leukemia
Status:
COMPLETED
Status Verified Date:
2023-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The proposed study is designed to combine crenolanib with standard salvage chemotherapy to treat patients with RR AML irrespective the FLT3 status
Detailed Description:
Open label dose de-escalation pilot trial of crenolanib with standard salvage chemotherapy Subjects may receive up to 2 cycles of induction with standard salvage chemotherapy followed by crenolanib Each arm will enroll approximately 24 patients 72 total stratification to each arm will be per physicians choice
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None